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Abstract
Valproic acid (VPA) is a commonly used drug to treat epilepsy and bipolar disorders. Known properties of VPA are
inhibitions of histone deacetylases and activation of extracellular signal regulated kinases (ERK), which cannot fully
explain VPA’s clinical features. We found that VPA induces the proteasomal degradation of DICER, a key protein in
the generation of micro RNAs. Unexpectedly, the concentration of several micro RNAs increases after VPA
treatment, which is caused by the upregulation of their hosting genes prior to DICER degradation. The data suggest
that a loss of DICER protein and changes in micro RNA concentration contributes to the clinical properties of VPA.
VPA can be used experimentally to down regulate DICER protein levels, which likely reflects a natural regulation of
DICER.
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Valproic Acid (VPA) is a widely used drug to treat epilepsy
[1], migraines [2] and bipolar disorders [3]. VPA is currently
being tested for the treatment of additional diseases, such as
spinal muscular atrophy, where it promotes inclusion of a
critical alternative exon into the SMN2 pre-mRNA [4]. In
addition, VPA is tested as an anti- cancer drug [5–7].
Despite its frequent clinical use, its mechanism of action is
not fully understood. The drug has both acute (within days) and
chronic (within two weeks) effects depending on the disease
treated. VPA was shown to block histone deacetylase (HDAC)
activity, suggesting one mode of action is changing gene
expression via chromatin modifications [8]. In addition, it was
found that VPA activates the ERK (extracellular signal-
regulated kinases) pathway and subsequently influences AP-1-
dependent gene expression [9]. However the molecular
mechanisms remained elusive. In addition to its inhibition of
enzymatic activities, VPA causes the proteasomal degradation
of HADC2 [10] and CREM binding protein (CBP) [11].
The effect of VPA on gene expression has been tested in
several cell systems using cDNA-based expression arrays.
VPA treatment of rat cortical neurons generates 1,303 changes
in mRNA expression [12]. Administration of VPA resulted in
121 changes in the brain of rats [13] and 11 changes in mice
brains [14].
A change in gene expression does not only manifest itself in
alterations of mRNA levels, but can also result in changes of
non-coding RNAs, such as miRNAs (micro RNAs). miRNAs are
22 nt long RNAs generated from longer precursor RNAs. First,
nuclear pri-miRNAs having characteristic secondary structures
are cleaved by the drosha/DGCR8 complex in the nucleus to
pre-miRNAs, which are transported into the cytosol where they
are processed to mature miRNAs by the RNase III DICER. In
general, miRNAs act in the repression of translation, but can
also acquire other functions after binding to target RNAs [15].
Similar to other RNAs, the expression of some miRNAs is
regulated by physiological stimuli, such as light/dark cycles in
the retina [16]. DICER levels are regulated by autophagy
through binding to the autophagy receptor NDP52 [17], which
shows that miRNA production is under physiological regulation.
Most miRNAs are relatively stable, with half-lives of several
days in cell culture [18]. There are an increasing number of
miRNAs shown to be involved in disease, for example,
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miR-134 is upregulated in epilepsy and its depletion reduces
the occurrence of seizures [19].
Here, we analyzed the molecular mechanism of VPA,
starting from genome-wide array analysis. Unexpectedly, we
found that VPA causes the proteasomal degradation of DICER.
In addition, VPA up regulates expression of several miRNA
hosting genes, which results in an increase of a subset of
miRNAs. Our data suggest that changes in miRNAs contribute
to VPA’s clinical features.
Results
Genome-wide array analysis of HEK293 cells treated
with Valproic Acid (VPA)
To investigate VPA’s molecular mechanism of action on
gene expression, we performed Affymetrix exon junction array
analysis using HEK293 cells. VPA is in clinical tests to treat
spinal muscular atrophy [20], as it promotes inclusion of exon 7
of the SMN2 gene. Therefore, we used inclusion of the
alternative exon 7 to determine the most effective
concentration of VPA. Using a reporter gene in HEK293 cells,
we found that 20 mM VPA gives the strongest effect after 12
hours of treatment (data not shown).
Thus, we tested the effect of 20 mM VPA in HEK293 cells
after 16 hours of treatment using genome wide exon junction
arrays. As shown in Figure 1A, VPA mainly changes the
transcription levels but not the splice site selection. VPA
changed 3,614 transcripts more than 1.5 fold, representing
10.8% of the 33,395 genes on the array. Unexpectedly, usage
of only 160 alternative exons was changed. The most likely
cause for the transcriptional deregulation is the inhibition of
histone deacetylation, which we tested by chromatin
immunoprecipitations. As expected, after six hours of VPA
treatment, we see an increase in H3K27 acetylation in 3 out of
4 genes (Figure 1B, C), supporting the idea that an increase in
histone acetylation causes most of the observed changes in
gene expression.
We next determined the biological pathways affected (Figure
S1 ), defined by the KEGG database [21]. Unexpectedly for an
HDAC inhibitor, we found statistically significant enrichment of
genes affecting SNARE (Soluble NSF Attachment Protein
Receptor) interactions in vesicular transport, MAPK pathways
and endocytosis (p values < 10-3). This suggests that VPA
Figure 1.  VPA changes gene expression.  A. Overview of array analysis. HEK293 cells were treated for 16 hours with 20 mM
Valproic Acid and compared with untreated cells using Affymetrix Exons Junction Arrays. About 11% of all human genes show
changes on the transcriptional level, as indicated in the pie chart.
B. Chromatin immunoprecipitations using an H3K27ac antiserum on HEK293 cell lysates after six hours of VPA treatment. Promoter
regions of genes influenced by VPA (Figure S2) were tested.
C. Statistical analysis of three independent experiments.
doi: 10.1371/journal.pone.0082895.g001
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treatment does not affect gene expression uniformly, but
targets distinct pathways. The complete array analysis,
including the changes in alternative splicing and the pathway
analysis is shown in Figure S2 as a spreadsheet.
RT-PCR analysis showed the array data to be highly
reproducible with a validation rate of about 80% (13/16 genes
tested, Figure S3; Figure 2A, B). All genes tested showed a
change in gene expression that continuously increased from
zero, six and 12 hours of VPA treatment. Due to its central role
in miRNA production, we further validated the effect of VPA on
dicer mRNA and by end-point and real time PCR, which
supported the decrease of DICER mRNA indicated by the array
analysis (Figure 2A, B).
In summary, the array analysis indicated that VPA mainly
affects overall gene expression and causes a coordinated
change in distinct biological pathways. The targeting of defined
pathways is in agreement with VPA’s use as a drug causing
specific physiological effects.
mRNA changes caused by VPA are reflected on the
protein level
Next we used selected antisera to test whether the changes
detected on mRNA levels are also apparent on protein levels.
We performed Western Blot analysis on protein lysates from
HEK293 cells treated for 16 hours with 20 mM VPA. As shown
in Figure 1C, genes that change their expression levels after
VPA treatment also alter the expression level of the encoded
proteins.
In four of five cases, the change in protein expression
correlated with the mRNA regulation, as a drop or increase in
mRNA caused a similar change in protein concentration.
However, the syntaxin 2 gene (STX2) showed a slight
downregulation of mRNA (Figure S3), but a strong increase of
protein level (Figure 2C). These data indicate that in addition to
influencing gene expression, VPA has an additional,
posttranscriptional effect on protein expression.
Figure 2.  Validation of VPA induced changes.  A. Effect of VPA on dicer and LSM8 mRNA expression after 6 and 12 hours of
treatment, determined by RT-PCR (*: p < 0.05, from three independent experiments). H2O was used as negative control (ctl).
B. Real time PCR analysis of DICER mRNA expression after VPA treatment for six and 12 hrs.
C. Changes on protein level determined by Western Blot. HEK293 cells were treated for 16 hours with 20 mM VPA. Total cell
lysates were separated by SDS page and analyzed using the antisera indicated. Beta-actin was used as a loading control. The
mRNA changes of these genes are shown in Figure S3, VAMP8: downregulated, STX7: upregulated; STX2: downregulated; LSM8:
downregulated.
doi: 10.1371/journal.pone.0082895.g002
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VPA down regulates DICER protein levels
We next investigated DICER in more detail. Dicer mRNA is
about 50% down regulated by VPA (Figure 2A). Using a
previously described anti DICER antiserum [22], we detected a
strong downregulation of DICER protein in HEK293 cells. We
therefore raised a new DICER antiserum in goat (Figure S4)
and found a similar down regulation of DICER protein (Figure
3A). After VPA treatment, DICER protein can only be detected
by extended exposure of Western Blots made from HEK293
cells. A similar effect of DICER protein loss after VPA treatment
was seen in Rhabdomyosarcoma cells (RH18) and
adenocarcinomic human alveolar basal epithelial cells (A549),
as well as in primary human fibroblasts (Figure 3A). We also
tested HeLa cells and found that they express very low levels
of DICER protein, which were reduced further by VPA
treatment (data not shown). These data suggest that the
reduction of DICER by VPA is common to cells.
Time and concentration dependency of VPA acting on
DICER protein levels
We next determined the concentration of VPA needed for
DICER protein degradation and its time course. DICER protein
levels significantly drop after 12 hours of treatment using 20
mM VPA (Figure 3B) in HEK293 cells, although mRNA can still
be detected (Figure 2A). We then analyzed different
concentrations at 16 hrs of treatment and found that VPA
effectively reduces DICER protein when VPA is present in a
concentration between five and 10 mM (Figure 3C). This
concentration range is comparable to levels seen in serum of
patients treated with VPA that range from 1-5 mM [23].
VPA acts on DICER protein via the proteasome
Next, we investigated whether VPA acts on the pre-mRNA of
dicer and expressed DICER from cDNA constructs that lack
introns. As shown in Figure 4A, VPA causes a strong decrease
of both endogenous and RFP-tagged DICER, suggesting that
VPA acts after pre-mRNA splicing.
Therefore, we tested the proteasome and lysosome as
potential posttranslational degradation mechanism.
Proteasomal degradation was blocked using the inhibitors
MG132 [24]. Lysosomal action was inhibited using bafilomycin
A1 [25]. As shown in Figure 4B, DICER degradation was
blocked when the proteasome was inhibited by MG132,
whereas the lysosomal inhibitor bafliomycin had no effect. The
difference between MG132 and Bafliomycin on rescuing
DICER degradation through VPA was significant (Figure S5),
suggesting that VPA causes a proteasomal degradation.
To further analyze the role of the proteasome, we analyzed
the ubiquitination of DICER protein and determined whether
VPA causes a change in DICER ubiquitination. We
immunoprecipitated endogenous DICER from cells transfected
with HA-tagged ubiquitin expression constructs under
denaturing conditions in RIPA buffer. In these experiments, the
proteasome was blocked by addition of MG132. Probing these
immunoprecipitates with an anti-HA antiserum detected a basal
ubiquitination of DICER that is strongly increased when VPA is
added to the cells (Figure 4C). Importantly, even in the
absence of VPA, we can detect a small amount of
ubiquitination of DICER, suggesting that ubiquitination and
likely proteasomal degradation is part of a physiological
regulation of DICER levels.
We next blocked protein synthesis using cycloheximide and
determined the effect of VPA on DICER expression. After 16
hrs of treatment, there is about 20% decrease of DICER
protein, suggesting that DICER has a long half-life in HEK293
cells. The addition of VPA to cycloheximide-treated cells
caused loss of DICER expression, suggesting that the effect is
post-translational (Figure 4D).
As a further control, we treated cells with MB132 or
Bafliomycin and observed no change in DICER expression,
demonstrating that the loss of DICER is caused by VPA (Figure
4E). Since DICER was reported to be degraded by autophagy
[17], we verified the effectiveness of bafliomycin using the
microtubule-associated protein light chain 3 (LC3) as an
autophagy marker [26]. As shown in Figure 4F, bafliomycin
stabilized LC3-II, demonstrating that it blocks autophagy and
worked in the assays.
Together, the data suggest that similar to HDAC2 and CBP
[10,11], VPA causes the proteasomal, but not lysosomal
degradation of DICER.
VPA Changes the miRNA Profile of HEK293 Cells
Human and mouse cells contain only one copy of the dicer
gene critical to generate miRNAs. The homozygous disruption
of dicer in mice is embryonic lethal, leads to the loss of
miRNAs and an accumulation of double-stranded RNAs in
stem cells [27]. However, several miRNAs can be made
independently of DICER, for example by using the RNAse
activity of argonaute 2 [28]. To test the effect of DICER
depletion, we performed miRNA array analysis of HEK293 cells
that were treated with 20 mM VPA for 16 hours. This treatment
leads to an almost complete depletion of DICER protein (Figure
3A). From the 870 miRNAs present on the array, 117 human
miRNAs were deregulated by VPA treatment. Unexpectedly, 49
miRNAs were markedly up regulated, despite the loss of
DICER (Figure S6 and Figure S7). We next analyzed seven of
the deregulated miRNAs by TaqMan analysis, which
discriminates between mature miRNAs and pre-miRNAs. We
could validate all changes in miRNAs tested (Figure 5A).
Therefore, VPA up regulates some miRNAs, which is an
unexpected property of the drug. The PCR-based assay was
further validated for miR-194 using RNAse protection. We used
a probe against the pri-miRNA and observed the upregulation
of the mature miRNA (Figure 5B), which further validates the
PCR results.
Since VPA upregulates several genes, it is possible that an
increase of certain miRNAs is caused by an increase of their
hosting genes. We therefore determined the concentration of
pri-miRNAs hosting miRNAs that increase in response to VPA.
We measured pri-miRNAs using RT-PCR employing flanking
primers schematically indicated in Figure 5C. In cells treated
for 16 hours with VPA we found that pri-miRNAs change
similarly to the miRNAs they host. This suggests that VPA
increases the expression of some miRNA hosting genes, which
could explain the increase of some miRNAs after VPA
treatment.
Valproic Acid Causes DICER Degradation
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Figure 3.  Influence of VPA on DICER protein expression levels.  A. Effect of VPA on DICER protein level in different cell lines.
The cell lines indicated were treated with 20 mM VPA for 16 hours and the expression of DICER was detected using Western blot.
Beta actin was used as a loading control in each cell line.
B. Time course of DICER expression in HEK293 cells treated with 20 mM VPA. DICER protein level is significantly reduced after 12
hours of VPA treatment. To quantify the effect, we calculated the intensity of DICER protein signal normalized to ß-actin, shown
below, n=3.
C. Concentration dependency of DICER degradation in HEK293 cells during 16 hours of treatment.
doi: 10.1371/journal.pone.0082895.g003
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VPA treatment changes translation from miRNA
reporter constructs
Next, we determined whether VPA treatment could have a
functional effect on miRNA targets. We used luciferase
constructs containing miR-129 binding sites derived from the
CDK6 3’ UTR as reporters, as this miRNA showed the
strongest upregulation after VPA treatment and is a known
regulator of CDK6 [29]. The reporters were transfected into
HEK293 cells, which were subsequently treated with VPA for
16 hours. As shown in Figure 6A, B, we see a decrease in
luciferase expression in constructs that contain the miR-129
binding site. Since miR-129 is highly up regulated by VPA
(Figure 5A), this suggests that VPA-mediated changes in gene
expression can influence translation of target genes
Figure 4.  VPA leads to a degradation of the RNAse III DICER.  A. Influence of VPA on DICER over expressed as a cDNA.
HEK293 cells were transfected with RFP-tagged DICER and treated for 16 hours with 20 mM VPA. Proteins were separated on
SDS page and analyzed by western blot using anti-DICER antisera.
B. Proteasome inhibitors block the action of VPA on DICER.
HEK293 cells were treated with 20 mM VPA in the presence of the proteasome inhibitor MG132 (10 µM), as well as the lysosome
inhibitor bafliomycin A1 (200 nM) for 16 hours. Expression of endogenous DICER was detected using Western blot (top) and
compared to ß-actin expression (bottom). The quantification is shown in Figure S5.
C. Ubiquitination of DICER: HEK293 cells were transfected with a HA-tagged ubiquitin expression vector, in the presence of 10 µM
MG132. Endogenous DICER was immunoprecipitated using anti-DICER antiserum, and analyzed with an anti-HA antiserum. VPA
treatment was for 16 hours. The western blot with anti-DICER antiserum is shown below.
D. Effect of VPA on cells after inhibition of translation. Cells were treated with cyclohexamide (100 mg/l) and 20 mM VPA for 12 hrs
and DICER protein levels detected by western blot. ß-actin was used to demonstrate loading. The quantification underneath shows
the fold change relative to the water control, set to 1, n=3.
E. HEK293 cells were treated with 20 mM VPA, 10 µM MG132 and 200 nM bafliomycin A1 and DICER was detected by western
blot. ß-actin was used as a loading control. The signal for DICER relative to actin was set to 1, VPA:0.36; MG132:0.93; Bafliomycin:
1.
F. Response of LC3 protein levels to bafliomycin, MG132 and VPA treatment. Cells were treated for 12 hours with the drugs and the
conversion of LC3-I to LC3-II was monitored by Western blot.
doi: 10.1371/journal.pone.0082895.g004
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Figure 5.  Change of miRNAs and their hosting genes after VPA treatment.  A. Validation of miRNA expression changes
detected by array analysis in VPA treated cells. Real-time PCR was performed using TaqMan probes (*: p < 0.05, **: p < 0.01, ***: p
< 0.001, n>4).
B. Validation of VPA-dependent miR-194 upregulation using RNAse protection. A probe complementary to pri-miR-194 was used
and protected the mature miRNA. A precursor form is faintly visible (triangle).
C. Changes in expression of the pri-miRNA genes detected by RT-PCR.
The location of the miRNA amplification primers is schematically indicated. The primer sequences are given in Figure S8.
doi: 10.1371/journal.pone.0082895.g005
Figure 6.  VPA regulates miR-129 containing reporter genes in cis and trans.  A. Schematic diagram of the reporter construct
indicating the location of the miRNA binding sites (small box) in the UTR of the hRluc gene.
B. HEK293 cells were transfected with dual luciferase reporter genes containing miR-129 binding sites (1, 2). Renilla luciferase
activity was subject to the regulation of miR-129 binding site. Firefly luciferase activity from the same reporter construct was used to
normalize and to generate relative activity of Renilla luciferase. Ctl. is a luciferase construct without the miR-129 binding sites. The
fold-change of relative luciferase activities Renilla/Firefly is shown. The transfected cells were treated with 20 mM VPA for 16 hours.
The binding sequences for miR-129 were: 1: CACACAGCAAAAA; 2: GCAAAAA; Control sequence: TTTATTT.
doi: 10.1371/journal.pone.0082895.g006
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Discussion
VPA changes gene expression of distinct biological
pathways
To gain insight into VPA’s molecular action, we performed
genome-wide array analysis. We detected massive changes in
overall gene expression that affected about 11% of the
annotated genes. Most of the genes showed increased
expression in response to VPA: 2,667 genes were up regulated
and 947 were down regulated, which is in agreement with an
inhibition of histone deacetylation that opens chromatin for
transcription. Using H3K27Ac as an acetylation marker, we
observed fast changes in three out of four genes. It is likely that
VPA affects other histone acetylation events as well. VPA did
not affect pathways indiscriminately, as pathways dealing with
intracellular traffic and MAP kinases were disproportionally
affected, indicating VPA has additional mechanisms of action.
VPA causes a loss of DICER protein
Using array analysis and PCR-validation, we detected a
modest down regulation of the dicer pre-mRNA. A subsequent
validation of the effect on the protein level showed a loss of
DICER protein. DICER is hardly detectable after 16 hours of
VPA treatment in all cell lines tested. The DICER protein loss is
also seen when the protein is generated from transfected
cDNAs, suggesting a posttranslational mechanism. The
proteasomal inhibitor MG132 blocks the disappearance of
DICER. Using over expressed ubiquitin, we could detect
ubiquitination of DICER that is strongly increased by VPA
treatment, indicating VPA promotes an ubiquitination of DICER
by an unknown mechanism.
It has been recently reported that DICER is degraded by
autophagy [17]. Since we cannot reverse the effect of VPA
using the lysosomal inhibitor bafliomycin, but can reverse the
effect with the proteasomal inhibitor MG132, it is likely that VPA
causes degradation only in the proteasome. This suggests that
cells can degrade DICER both in the proteasome and through
autophagy using distinct pathways.
To our knowledge, proteasomal degradation of DICER has
not been reported. Since there is detectable ubiquitination of
DICER in untreated HEK293 cells, it is possible that VPA
enhances a naturally signaling pathway controlling DICER
degradation. The ubiquitination of DICER is low in untreated
cells, and physiological signals that increase the ubiquitination
remain to be determined.
VPA promotes similar proteasomal degradation of two other
proteins, HADC2 [10] and CREM binding protein (CBP) [11],
suggesting targeted protein degradation is part of the VPA’s
mode of action. It is possible VPA causes the degradation of
other proteins as well. Previously, a genome-wide proteomics
analysis revealed DICER is associated with the
deubiquitination enzyme USP49 [30], which further supports
endogenous ubiquitination of DICER. It is possible VPA
interferes with USP49 acting on DICER. We also noticed that
VPA causes a downregulation of LSM8/NAA38. This protein
has a dual function as a spliceosomal U6 component and a
component of the N-(alpha)-acetyltransferase complex that co-
translationally transfers an acetyl group to the first methionine
of certain proteins [31]. It is possible that loss of this acetylation
contributes either directly of indirectly to the degradation of
DICER.
VPA paradoxically increases the concentration of some
miRNAs
The loss of DICER protein is expected to reduce miRNAs, as
canonical miRNAs disappear in genetic dicer knockouts
[27,32,33]. We tested this hypothesis using genome-wide
miRNA arrays and surprisingly found that most miRNAs do not
change significantly after DICER loss. This is likely due to the
stability of miRNAs, which has been estimated to be around
five days for most miRNAs [18]. We found some miRNAs to be
reduced within 16 hours of VPA treatment, which reflects about
four hours without DICER protein. This supports earlier findings
that some miRNAs are relatively unstable and undergo rapid
turnover [16,18].
VPA treatment causes almost complete degradation of
DICER, but does not change expression of 87% of miRNAs.
This suggests that VPA acts predominantly on DICER that is
free from bound miRNAs.
Unexpectedly, we found VPA up regulates some miRNAs,
which is a unique feature of VPA’s mode of action. The up
regulation is likely due to the different time course for VPA
mediated increase in transcription of miRNA hosting genes and
the decrease of DICER protein through degradation.
Transcriptional changes occur within six hours of VPA
treatment, whereas it takes more than 12 hours for DICER
protein to significantly drop in cell culture. This could explain
why we found an increase of several miRNAs after VPA
treatment, as the hosting genes of these miRNAs are activated
by VPA, likely through an increase of histone acetylation in
their promoters. It is however possible that the up regulated
miRNAs are generated by a DICER independent mechanism,
for example through argonaute2 that processes some miRNAs
[28].
An analysis of pathways common to all up regulated miRNAs
using DIANA [34] identified “melanogenesis” as the most
affected pathway. Valproic acid has been shown to increase
melanin production and inhibit the proliferation of melanoma
cells [35]. It remains to be determined whether the effect of
VPA on melanoma cells is acting through a change in miRNAs.
The influence of VPA on both transcriptional regulation and
DICER expression distinguishes VPA action from genetic dicer
knockouts or siRNA mediated changes that show a general
loss of mature miRNAs [27,33,36].
Due to its short half-life of 9-12 hours in humans, VPA serum
concentrations fluctuate between peak and trough levels in
serum [37]. It could therefore be possible that part of VPA’s
mode of action is the repeated increase of pri-miRNA
expression and dicer reduction, which could result in an
increase of some miRNAs. In addition, it is possible that DICER
levels recover during trough times in patients, which could
contribute to the physiological response, as it allows the
generation of miRNAs from an altered pri-miRNA pool.
Valproic Acid Causes DICER Degradation
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Regulating DICER protein concentration is a
physiological event
Dicer mRNA expression is controlled by extracellular signals,
such as serum withdrawal which reduces dicer mRNA [38].
Cellular stress caused by reactive oxygen species and Ras
activation reduces DICER protein levels [39], indicating DICER
levels are regulated. On an organismal level, DICER protein is
reduced by pathophysiological events in several diseases.
DICER is decreased in geographic atrophy (GA), a form of
age-related macular degeneration leading to blindness [40].
DICER is also reduced in dilated cardiomyopathy, which can
be reversed by ventricle assist devices [33], demonstrating
DICER deregulation can be reversed in vivo.
In relation to the use of VPA as an anti-epileptic drug, the
finding that DICER protein is reduced in temporal lobe epilepsy
(TLE) with hippocampal sclerosis is most interesting [41].
Experimentally induced seizures in mice cause a similar loss of
DICER in affected brain regions. VPA could interfere with these
systems by upregulating miRNA hosting genes.
In summary, we found VPA is a useful drug in manipulating
miRNA metabolism for research purposes. Regarding its
medical use, we identified an unexpected property of Valproic
Acid: it changes miRNA composition and uniquely upregulates
some miRNAs by simultaneously changing the expression of
miRNA hosting genes and by causing the degradation of
DICER. It is likely this paradoxical increase of miRNAs
contributes directly to the physiological effects of VPA.
Materials and Methods
Exon junction arrays
RNA was isolated using Qiagen RNA purification columns.
Its quality was determined by RNA integrity (RIN) number
analysis and samples with a RIN >9.5 were used following the
Affymetrix labeling procedure.
For the analysis, the signal from Affymetrix human junction
arrays (HJAY) was normalized using the “Probe scaling”
method. The background was corrected with ProbeEffect from
GeneBase [42]. The gene expression index was computed
from probes were selected using ProbeSelect from GeneBase
[42]. The gene expression signals were computed using these
probes. Genes were considered expressed if the mean
intensity was ≥ 500. Genes were considered regulated if (1)
they were expressed in at least one condition (for example,
VPA and/or control), (2) the fold-change was greater or equal
than 1.5 and (3) the unpaired t-test p-value between gene
intensities was ≤ 0.05. For each probe, a splicing-index was
computed. Unpaired t-tests were performed to determine the
difference in probe expression between the two samples as
described previously [43]. Probe p-values in each probeset
were then summarized using Fisher's method. Using
annotation files, splicing patterns (cassette exons, 5’/3’
alternative splice sites and mutually exclusive exons) were
tested for a difference between isoforms, selecting the ones
with a minimum number of regulated probeset (with a p-
value ≤ 0.01) in each competing isoform (at least one third of
“exclusion” probesets have to be significant and at least one
third of “inclusion” probesets have to be significant and show
an opposite regulation for the splicing-index compared to the
“exclusion” probesets). For example, for a single cassette
exon, the exclusion junction and at least one of the three
inclusion probesets (one exon probeset and two inclusion
junction probesets) have to be significant and have to show an
opposite regulation for the splicing-index.
Pathway Analysis
Significant KEGG pathways [21] were retrieved using DAVID
[44]. The p-values given are essentially more stringent Fisher’s
Exact Tests, as the classical Fisher’s p-value is calculated after
subtracting 1 from the number of genes changed in a given
pathway, which is then analyzed using Fisher’s Exact Test.
MicroRNA microarray
RNA was isolated using Trizol (Invitrogen). Its quality was
determined by RNA integrity (RIN) number analysis and
samples with a RIN >9.5 were used following the Affymetrix
labeling procedure for miRNA Array version 1.0. Data were
analyzed using Affymetrix Expression Console™ Software.
Cell culture
The HEK293, HeLa, and A549 cells were obtained from the
American Type Culture Collection (ATCC). RH18 cells were
obtained from St. Jude Children’s Research Hospital and were
described in [45]. The primary human fibroblast cells were
obtained from Coriell Institute (GM 00498D), described in [46].
All the cells were grown in the recommended medium
containing 10% fetal bovine serum (FBS) at 37 °C under 5%
CO2.
Cloning
For the construction of pRFP-Dicer, the PCR-amplified full
length coding Dicer sequence was inserted into pRFP vector (a
generous gift from Dr. Emilia Galperin) using the restriction
sites NheI and AgeI.
Western Blot
Cells were washed with PBS and then lysed using 200 μl
RIPA buffer on ice for 20 minutes. Lysates were collected in
Eppendorf tubes, cleared by centrifugation for 1 minute at
12,000 rpm. The supernatant was collected and the
concentration was measured using a Bradford staining (Bio-
Rad). Equal amounts of protein from each sample were loaded
on SDS polyacrylamide gels. Proteins resolved on SDS
polyacrylamide gels were transferred to nitrocellulose
membranes (Schleicher and Schuell) in transfer buffer for 45
minutes at 120 V. After the transfer, the membranes were
blocked three times for 20 minutes in 1 × NET-gelatine buffer at
room temperature. Primary antibodies were diluted to 1:1000,
then added and incubated overnight at 4 °C. The next day, the
membranes were washed three times for 20 minutes in 1 ×
NET-gelatine and then incubated with horseradish peroxidase
coupled secondary antibodies for 2 hours. The membranes
were subsequently washed three times for 20 minutes in 1 ×
NET-gelatine and the bound antibodies were detected using
the ECL system.
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RT-PCR
400 ng of total RNA (200 ng/µl), 5 pmol of reverse primer
and 40 U of SuperScript III reverse transcriptase (Invitrogen)
were mixed in 5 µl of RT buffer. To reverse transcribe the RNA,
the reaction was incubated at 55 °C for 50 minutes. One-third
of the RT reaction was used for cDNA amplification. The
reaction was performed in 25 µl and contained 10 pmol of
specific forward and reverse primers, 200 µM dNTPs, 1 x Taq
polymerase buffer and 1 U of Taq DNA polymerase. The
amplification was carried out in an Eppendorf PCR System
Thermocycler under the following conditions: initial
denaturation for 4 minutes at 94 °C, 30 cycles for 30 seconds
at 94 °C, 30 seconds at 60 °C and an extension of 1 minute at
72 °C. After the last cycle, the reaction was held for 5 minutes
at the extension temperature to complete the amplification of all
products.
The fold change was estimated as follows: 2Ct(reference)-Ct(sample),
where Ct (reference) and Ct (sample) were control group and
VPA treatment group, respectively. For each experiment, at
least three independent experiments were analyzed.
Drug treatment
Exponentially growing HEK293 cells were split at a density of
about 3 x 105 cells / 8 cm2. 24 hours later, cells were treated
with sodium valproate (Sigma) dissolved in water at
appropriate concentration for the indicated times in the different
experiments. The final concentrations were, Bafilomycin A1
200 nM; MG132 10 µM, all from Sigma.
TaqMan analysis
5 ng of total RNA, 1 x RT primer, 15 mM dNTPs, 50U of
SuperScript III Reverse Transcriptase, 1 x Reverse
Transcription buffer, 4U of RNase inhibitor were mixed in a 15
μl RT reaction. The reverse transcription was performed under
the following condition: 30 minutes at 16 °C, 30 minutes at 42
°C and 5 minutes at 85 °C.
One-fifth of the RT reaction was used for the qPCR reaction.
The reaction was performed in 20 µl and contained 1 x TaqMan
MicroRNA assay primer, 1 x TaqMan universal PCR Master
Mix no AmpErase UNG (Applied Biosystems). The
amplification was carried out in a Stratagene Mx3000p
Thermocycler under the following conditions: initial
denaturation for 10 minutes at 95 °C, 40 cycles for 15 seconds
at 95 °C and an extension of 1 minute at 60 °C. The TaqMan
assay number for miR-129 is 000590; for miR-519e* is 1166;
for miR-194 is 000493; for miR-214 is 002306; for miR-449a is
001030; for miR-182 is 002334; for miR-92a-1* is 002137. A
list of primers for validations is given in Figure S8.
Antiserum generation
An anti-dicer serum was raised in goat using the peptide
ETSVPGRPGSTKRRQC. The second and third bleeds were
pooled and affinity purified using the peptide. The Anti-CD63
antibody was purchased from Abcam, and anti-β-actin antibody
was obtained from Sigma.
Luciferase assay
HEK293 cells were seeded in 24 well plates, and were
transfected with psiCHECK2 dual luciferase reporter plasmids
containing miR-129 targeting sites (1 µg/300,000 cells). 24
hours post transfection, cells were lysed and luciferase
activities were measured according to manufacturer’s
instruction using the Dual-GloTM Assay System (Promega).
Data were normalized to the activity of the firefly luciferase
expressed from the same psiCHECK2 vector as the internal
control.
Sequence for miR-129 target 1: CACACAGCAAAAA
Sequence for miR-129 target 2: GCAAAAA
Sequence for control: TTTATTT
In Vivo Ubiquitination Assay
HEK293 cells were seeded in 6 well plates. Cells were
transfected with an HA-ubiquitin expressing plasmid and were
subsequently treated with 20 mM VPA and 10 μM MG132 for
16 hours. Cells were lysed in RIPA buffer. HA-ubiquitin-
conjugated proteins were purified with anti-Dicer antisera and
protein A/G beads (Thermo Scientific). The presence of HA-
ubiquitin–conjugated Dicer protein in the immunoprecipitates
was detected by immunoblotting with the anti-HA monoclonal
antibody 2-2.2.14 (Thermo Scientific).
RNAse protection experiments
Were performed as previously described [47,48] using a
probe against pri-miR-194 (hg19:
chr11:64,658,827-64,658,911) and 40 µg of HEK293 total RNA
and 80,000 cpm of 32P-labeled probe, generated with alpha
UTP (800 Ci/mmol) as the only source of UTP.
Chromatin immunoprecipitations
HEK293 cells, treated and not with VPA, were pelleted at
1,000 rpm at 4 °C and washed in ice-cold PBS buffer. The cell
pellet was resuspended in ice-cold NP-40 lysis buffer (10 mM
Tris [pH 7.4], 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 0.15 mM
spermine, 0.5 mM spermidine) and incubated on ice for 5
minutes. The solution was centrifuged at 3,000 rpm for 10
minutes. The nuclear fraction (pellet) was then resuspended in
1 ml of ice-cold MNase digestion buffer (10 mM Tris [pH 7.4],
15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM
spermidine, 1 mM CaCl2) and digested with 50 U/ml MNase at
37˙C for 12 minutes. The reaction was stopped by addition of
EDTA and NP-40 to an end concentration of 0.01 M and 0.1%
respectively. Reactions were digested with RNaseA (0.1 mg)
for 1 hr at 42 °C and further treated with Proteinase K at 37˙C
for 1 hour. The chromatin was immunoprecipitated for 14–16 h
at 4°C using specific antibodies to H3K27ac (AbCam). After the
incubation, chromatin immunoprecipitates were purified, and
then 2 µl of each sample were analyzed by real-time PCR.
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Supporting Information
Figure S1.  Summary of the Exon-junction array analysis.
Kyoto Encyclopedia Genes and Genomes (KEGG) pathway
analysis of the genes showing transcriptional changes. The p-
value indicates the confidence that the given pathway is
changed, calculated with a more stringent version of Fisher’s
exact test.
(PPTX)
Figure S2.  Array analysis in Excel format. Excel file
summarizing the array analysis.
(XLS)
Figure S3.  Validation of Array Results by RT-PCR. A. RT-
PCR analysis of HEK293 cells that were treated for 0, 6 and 12
hours with 20 mM VPA.
B. Statistical evaluation of the changes in three independent
experiments. The expression level in untreated HEK293 cells
was set to 1. (*: p < 0.05, **: p < 0.01, ***: p < 0.001, n>4).
(PPTX)
Figure S4.  Testing of the DICER antisera. Goats were
immunized with the peptide ETSVPGRPGSTKRRQC and final
sera were analyzed at the indicated dilutions. Similar to other
DICER antisera, a cross reactivity is seen around 60kDa.
(PPTX)
Figure S5.  Quantification of the effect of MG132 and
Bafliomycin on VPA mediated DICER degradation. The
DICER signal was normalized to beta-actin and the ratio in the
water treated control was set to 1; n=3. A representative
experiment is shown in Figure 4B.
(PPTX)
Figure S6.  Summary of miRNAs changes after VPA
treatment. HEK293 cells were treated with 20 mM VPA and
changes in miRNAs monitored by array analysis. The table lists
miRNAs with the highest fold-changes and their experimentally
validated target genes from the literatures.
(PPTX)
Figure S7.  Array analysis in Excel format. Summary of
miRNAs changes after VPA treatment.
(XLSX)
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